drugset / Trial / NCT07228039

ESP Blocks for Posterior Spinal Fusion

NCT07228039

Phase 4 Not yet recruiting 75 enrolled Duke University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This prospective randomized double-blind study evaluates the efficacy of erector spinae plane (ESP) blocks on postoperative pain in patients undergoing cervical or lumbar posterior spinal fusion. Patients will receive either 0.5% bupivacaine plus liposomal bupivacaine or 0.5% plain bupivacaine. Outcomes include opioid consumption over 72 hours, pain scores, length of stay, and time to ambulation.

Timeline

Start
2026-07
Primary completion
2028-01
Completion
2028-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 0.5 % Other

Indications

No indication recorded.